Status:
UNKNOWN
Preoporative Bevacizumab, Radiation Therapy, and XELOX Chemotherapy for Locally Advanced Nonmetastatic Rectal Cancer
Lead Sponsor:
Sun Yat-sen University
Conditions:
Rectal Cancer
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
We presumed that the addition of a monoclonal antibody Bevacizumab into radiation therapy and combination chemotherapy could results in improved pathologic tumor regression grade (TRG) in locally adva...
Detailed Description
Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Giving bevacizumab together with radiation therapy and combination chemotherapy before surgery may achieve promisi...
Eligibility Criteria
Inclusion
- Histologically confirmed adenocarcinoma of the colon or rectum.
- T3 or T4 adenocarcinoma or node positive colorectal tumours.
- Appropriate staging investigations of the primary tumour, either endorectal ultrasound or pelvic MRI.
- Male or female aged 18 to 70.
- Have a performance status ECOG of 0 or 1.
- Have a life expectancy greater than 6 months.
- Adequate organ function and coagulation parameters as measured by: WBC \> 4000/mm3, PLT \> 100000/mm3, Hb \> 10g/dL, ALT \< 1.5X ULN, AST \< 1.5X ULN, bilirubin \< 1.5mg/dL Serum creatinine \< 1.8mg/dL.
- Patient consent.
Exclusion
- Known to have clinical or radiological evidence of distant metastases.
- Evidence of intestinal obstruction (except for those after enterostomy).
- Patients with a past history of colorectal surgery (except for enterostomy), chemtherapy, radiation, biotherapy or targeted therapy.
- Pregnant woman OR women of childbearing potential with a positive pregnancy test at baseline or lactating.
- Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study.
- Patients with a past or current history (within last 5 years) of other malignancies, except for the indication under this study and curatively treated basal and squamous skin cancer or in-situ cancer of the cervix.
- Patients with mental disorder unable to complete the informed consent.
- Uncontrolled hypertension.
- Clinically significant (i.e. active) cardiovascular disease for example:
- cerebrovascular accidents (\<=6 months), myocardial infarction (\<= 6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication.
- Moderate or serious proteinuria.
- Known hypersensitivity against experimental drugs.
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2020
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT01818973
Start Date
March 1 2013
End Date
March 1 2020
Last Update
June 8 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University Cancer Center (SYSUCC)
Guangzhou, Guangdong, China, 510060